Humana (NYSE:HUM) Stock Rating Upgraded by ValuEngine

Humana (NYSE:HUM) was upgraded by investment analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday, ValuEngine reports.

HUM has been the topic of several other research reports. Barclays set a $24.00 price objective on shares of Tenet Healthcare and gave the stock a “hold” rating in a research note on Wednesday, April 17th. Citigroup lowered shares of BCE from a “buy” rating to a “neutral” rating in a research note on Thursday, May 2nd. SunTrust Banks increased their price objective on shares of Markel to $1,100.00 and gave the stock a “hold” rating in a research note on Thursday, May 2nd. Credit Suisse Group reiterated a “buy” rating and set a $19.50 price objective on shares of Infineon Technologies in a research note on Thursday, May 2nd. Finally, Oppenheimer dropped their price objective on shares of Littelfuse from $215.00 to $210.00 and set an “outperform” rating on the stock in a research note on Thursday, May 2nd. One investment analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have assigned a buy rating to the company. Humana presently has a consensus rating of “Buy” and an average price target of $336.42.

HUM traded up $11.06 on Friday, hitting $291.25. 2,039,470 shares of the company’s stock were exchanged, compared to its average volume of 1,348,647. The firm has a market capitalization of $36.18 billion, a price-to-earnings ratio of 20.02, a PEG ratio of 1.10 and a beta of 0.87. Humana has a twelve month low of $225.65 and a twelve month high of $355.88. The company’s fifty day simple moving average is $258.65. The company has a current ratio of 1.65, a quick ratio of 1.65 and a debt-to-equity ratio of 0.40.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, May 1st. The insurance provider reported $4.48 earnings per share for the quarter, topping the consensus estimate of $4.30 by $0.18. The firm had revenue of $16.11 billion for the quarter, compared to analyst estimates of $15.67 billion. Humana had a net margin of 2.99% and a return on equity of 20.77%. Humana’s quarterly revenue was up 12.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.36 earnings per share. On average, equities analysts expect that Humana will post 17.48 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Destination Wealth Management boosted its holdings in shares of Humana by 130.0% in the first quarter. Destination Wealth Management now owns 115 shares of the insurance provider’s stock valued at $31,000 after acquiring an additional 65 shares in the last quarter. Evolution Wealth Advisors LLC bought a new position in shares of Humana in the second quarter valued at approximately $46,000. Sontag Advisory LLC bought a new position in shares of Humana in the fourth quarter valued at approximately $47,000. Zions Bancorporation N.A. bought a new position in shares of Humana in the first quarter valued at approximately $51,000. Finally, Berman Capital Advisors LLC boosted its holdings in shares of Humana by 152.3% in the first quarter. Berman Capital Advisors LLC now owns 217 shares of the insurance provider’s stock valued at $57,000 after acquiring an additional 131 shares in the last quarter. Hedge funds and other institutional investors own 92.61% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Further Reading: Different Types of Derivatives

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.